This is a pilot clinical study of hyperpolarized pyruvate (13C) injection that includes the
acquisition of magnetic resonance (MR) data and will be performed in men with localized
prostate cancer. Part 1: Five patients will be evaluated for reproducibility of 13C HP MR
imaging measurements obtained 2-3 weeks apart with no interim treatment. Part 2: Five
patients will be evaluated for the change in 13C HP MR imaging measurements after 2 months of
ADT.
13C HP MR data will be acquired in two parts of the study (which can occur simultaneously):
Part 1: Patients will undergo imaging at baseline and will be repeated two to three weeks
later (with no intervention in the interim) to evaluate reproducibility.
Part 2: Patients will undergo imaging at baseline, initiate androgen deprivation therapy, and
undergo repeat imaging two months after initiation of ADT to evaluate the ability of the
imaging to reflect a metabolic response to treatment.
The change in pyruvate/lactate ratio and lactate levels will be measured and compared to
baseline at these timepoints.